市场调查报告书
商品编码
1520503
2024-2032 年尼古丁口香糖市场报告(按类型、应用、配销通路和地区)Nicotine Gum Market Report by Type, Application, Distribution Channel, and Region 2024-2032 |
2023年全球尼古丁口香糖IMARC Group规模达16亿美元。推动全球市场发展的因素有很多,包括戒烟措施和健康意识的提高、对方便的非处方(OTC)尼古丁替代疗法的需求不断增长,以及提高产品功效的技术创新。
主要市场驱动因素:人们对吸烟相关健康风险的认识不断提高,以及世界各地的各种戒烟倡议,正在成为成长诱导因素。
主要市场趋势:对非处方(OTC)尼古丁替代疗法的需求增加。再加上该产品在寻求戒烟的个人中的便利性和可及性的提高,正在支持市场的成长。
地理趋势:报告显示,由于注重健康的消费者数量不断增加,北美在市场上享有领先地位。
竞争格局:尼古丁口香糖产业的顶级参与者包括英美烟草、Cambrex Corporation、葛兰素史克、ITC Limited、强生服务、诺华、Perrigo、辉瑞、武田製药公司等。
挑战与机会:挑战包括需要克服与戒烟辅助工具相关的社会耻辱,并确保对尼古丁口香糖在戒烟过程中的作用进行适当的教育。儘管如此,尼古丁口香糖市场最近的机会是技术进步和公司之间的合作,以解决与吸烟相关的健康问题。
戒烟措施和健康意识
全球减少吸烟的努力以及健康意识的提高正在推动市场扩张。随着人们对吸烟相关健康风险的认识不断提高,人们正在积极寻找有效的戒烟策略。尼古丁口香糖是一种戒烟辅助剂,可透过逐渐并受控制地释放尼古丁来帮助使用者控制戒断症状。此外,医疗保健组织和监管机构的各种戒烟计画也为尼古丁口香糖的需求创造了有利的氛围。由于对公共卫生的重视以及消除吸烟的持续努力,人们越来越多地接受这种口香糖作为戒烟治疗的重要组成部分,这正在推动市场的成长。 2023 年 4 月 11 日,卫生部长尼尔·奥布莱恩 (Neil O'Brien) 在政策交流会上就政府降低吸烟率和解决未成年人吸电子烟问题的计划发表讲话,
对非处方尼古丁替代疗法的需求不断增长
根据IMARC Group的数据,到 2023 年,全球非处方药产业规模为 1,687 亿美元。推动市场的主要因素之一是对非处方尼古丁替代药物的需求不断增长。这种口香糖是一种易于取得的非处方药解决方案,使用户无需处方即可自行治疗。对于那些试图在不寻求医疗帮助的情况下戒烟的人来说,这种口香糖之所以受欢迎,是因为它的可及性和易用性。人们在管理健康方面变得更加积极主动,这为尼古丁口香糖市场前景提供了积极的前景。此外,2024 年1 月24 日,在奥里萨邦克塔克的Sri Ram Chandra Bhanja (SCB) 牙科学院和医院进行的一项临床试验揭示了尼古丁替代疗法(NRT) 与尼古丁替代疗法(NRT)合併使用时的显着疗效,这是戒烟工作的重大突破。
技术进步与产品创新
尼古丁替代疗法的配方和管理方面的持续技术改进和产品创新正在推动市场成长。尼古丁口香糖公司正在投入资金进行研发(R&D)活动,以提高产品的效能以及使用者体验。由于增强的口味和独特的输送系统等创新,用户正在采用这些口香糖。此外,加深对尼古丁成瘾和戒断过程的了解也有利于创造更有效的口香糖配方。对更有效的戒烟解决方案的需求不断增长,推动了尼古丁口香糖市场的成长。除此之外,市场上的公司正在获得公认机构的产品批准。例如,Perrigo Company plc (PRGO) 于2023 年5 月16 日获得美国食品药物管理局(FDA) 的尼古丁涂层薄荷含片2 毫克和4 毫克OTC 的最终批准。的消费者的戒断症状抽烟。此外,它将以零售商的商店品牌标籤进行销售,作为与 Nicorette 涂层冰薄荷含片相当的产品。
IMARC Group提供了每个细分市场的主要尼古丁口香糖市场趋势分析,以及 2024-2032 年全球、区域和国家层面的预测。我们的报告根据类型、应用和配销通路对市场进行了分类。
该报告根据类型提供了详细的市场细分和分析。其中包括 2 毫克尼古丁口香糖、4 毫克尼古丁口香糖和 6 毫克尼古丁口香糖。根据该报告,2 毫克尼古丁口香糖占最大份额。
那些希望在戒烟过程中减少尼古丁摄取的人会发现 2 毫克类别是合适的选择。 2 毫克尼古丁口香糖是控制戒断症状同时逐渐戒除尼古丁依赖的理想替代品,使其成为轻度至中度吸烟者的完美选择。此外,建议需要逐步戒烟策略和处于戒烟早期阶段的人们,以便能够更规范地转向无尼古丁的生活。
戒断诊所
医疗实践
个人吸烟者
其他的
医疗实践占据行业最大份额
报告还提供了基于应用程式的详细市场细分和分析。这包括戒断诊所、医疗实践、个人吸烟者等。报告称,医疗实践占据了最大的市场份额。
尼古丁口香糖用于医疗环境中更全面的戒烟计划。医生可能会向患者推荐这种口香糖,作为个人化戒烟方案的一部分或在常规咨询期间。尼古丁从口香糖中逐渐且受调节的释放与基于证据的疗法是一致的。在医疗实践应用中,强调了医疗保健专业人员在帮助人们戒烟方面的重要性,以及使用尼古丁口香糖带来的健康优势和个人化帮助。
零售药局
专卖店
网上商店
其他的
零售药局代表领先的细分市场
该报告根据配销通路对市场进行了详细的细分和分析。这包括零售药局、专卖店、网路商店等。报告称,零售药局是最大的细分市场。
尼古丁口香糖在零售药局很容易买到。寻找戒烟产品的消费者可以轻鬆地在家附近找到这些产品。这种口香糖很容易取得,药剂师可以提供与药物相关的建议,这使其成为那些寻求个人支持和快速获得戒烟产品的人的首选。
北美洲
美国
加拿大
亚太
中国
日本
印度
韩国
澳洲
印尼
其他的
欧洲
德国
法国
英国
义大利
西班牙
俄罗斯
其他的
拉丁美洲
巴西
墨西哥
其他的
中东和非洲
北美市场领先,占据最大的尼古丁口香糖市场份额
该报告还对所有主要区域市场进行了全面分析,其中包括北美(美国和加拿大);亚太地区(中国、日本、印度、韩国、澳洲、印尼等);欧洲(德国、法国、英国、义大利、西班牙、俄罗斯等);拉丁美洲(巴西、墨西哥等);以及中东和非洲。报告称,北美是尼古丁口香糖最大的区域市场。
由于戒烟努力强劲、健康意识提高以及庞大的消费者基础,北美成为一个重要的市场。该地区拥有完善的医疗基础设施和积极的监管措施,有助于这些口香糖作为首选戒烟辅助工具的普及。此外,在北美地区寻求有效戒烟解决方案的人数有所增加。除此之外,这些口香糖在零售药局和网路商店等各种分销管道上的广泛供应,有助于增加尼古丁口香糖市场收入。 2024年3月18日,全球领先的合约开发製造组织(CDMO)Cambrex宣布提前一年完成为期5年、1亿美元的投资策略。该项目将在其北美和欧洲药物开发和製造网络的 70% 范围内增加超过 150,000 平方英尺的产能和产能扩张,并将于 2024 年底完成。来解决与复杂分子相关的挑战。
市场研究报告也对市场竞争格局进行了全面分析。也提供了所有主要公司的详细资料。尼古丁口香糖产业的一些主要市场参与者包括英美烟草、Cambrex Corporation、葛兰素史克、ITC Limited、Johnson & Johnson Services、诺华、Perrigo、辉瑞、武田製药公司。
(请注意,这只是关键参与者的部分列表,报告中提供了完整列表。)
市场的主要参与者正在参与专注于产品创新、行销和协作的策略性倡议。主要製造商持续进行研发投资,旨在提高产品配方的有效性和吸引力。这些公司利用技术进步来创造新颖的输送机制、改进的口味和更好的味道掩蔽,满足消费者的喜好并推动市场成长。此外,强有力的行销活动以及与医疗保健组织的合作伙伴关係有助于提高个人对戒烟益处的认识,同时扩大消费者基础。行业利益相关者和监管机构之间的合作确保遵守健康标准并创造积极的市场环境。 2023 年 7 月 3 日,全球最大的独立消费者健康企业 Haleon 考虑出售其尼古丁口香糖业务,旨在精简业务。该公司正在与顾问合作,为其 Nicotinell 品牌的尼古丁口香糖寻找潜在的买家,该品牌的销售额可能价值约 8 亿美元。
The global nicotine gum market size reached US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.4 Billion by 2032, exhibiting a growth rate (CAGR) of 4.21% during 2024-2032. There are various factors that are driving the global market, which include smoking cessation initiatives and heightened health awareness, rising demand for convenient over the counter (OTC) nicotine replacement therapies, and technological innovations for enhancing product efficacy.
Major Market Drivers: The increasing awareness about health risks associated with smoking, along with various smoking cessation initiatives worldwide, are acting as growth-inducing factors.
Key Market Trends: There is a rise in the demand for over the counter (OTC) nicotine replacement therapies. This, coupled with the enhanced convenience and accessibility of the product among individuals seeking to quit smoking, are supporting the market growth.
Geographical Trends: According to the report, North America enjoys a leading position in the market due to the rising number of health-conscious consumers.
Competitive Landscape: Top players in the nicotine gum industry are British American Tobacco, Cambrex Corporation, GlaxoSmithKline, ITC Limited, Johnson & Johnson Services, Novartis, Perrigo, Pfizer, Takeda Pharmaceutical Company, among many others.
Challenges and Opportunities: Challenges include the need to overcome social stigmas associated with smoking cessation aids and ensure proper education about the role of nicotine gum in the quitting process. Nonetheless, nicotine gum market recent opportunities are technological advancements and collaborations among companies to address smoking-related health issues.
Smoking Cessation Initiatives and Health Awareness
Global efforts to reduce smoking, along with rising health awareness, are propelling the market expansion. People are actively looking for effective strategies to quit smoking as awareness about health risks connected with smoking increases among them. Nicotine gum is a smoking cessation aid that helps users manage the symptoms of withdrawal by releasing nicotine gradually and under control. In addition, various smoking cessation programs by healthcare organizations and regulatory authorities has created a favorable atmosphere for nicotine gum demand. The rising acceptance of this gum as an essential component of smoking cessation treatments due to the emphasis on public health and the ongoing efforts to eliminate smoking is impelling the market growth. On 11 April 2023, Neil O'Brien, Health Minister, delivered a speech at Policy Exchange on government plans to cut smoking rates and tackle underage vaping,
Growing Demand for OTC Nicotine Replacement Therapies
As per the IMARC Group, in 2023, the size of the OTC medication industry worldwide was US$ 168.7 Billion. One of the main factors propelling the market is the rising demand for OTC nicotine replacement medicines. This gum is an easily available OTC solution that enables users to self-administer therapy without a prescription. This gum's popularity as a top option for people trying to stop smoking without seeking medical help is due to its accessibility and ease of usage. People are becoming more proactive in managing their health, which is offering a positive nicotine gum market outlook. Furthermore, on 24 January 2024, in a significant breakthrough for tobacco cessation efforts, a clinical trial conducted at Sri Ram Chandra Bhanja (SCB) Dental College and Hospital in Cuttack, Odisha, unveiled the remarkable efficacy of nicotine replacement therapy (NRT) when combined with behavioral therapy.
Technological Advancements and Product Innovation
Continuous technological improvements and product innovations in the formulation and administration of nicotine replacement therapies are bolstering the market growth. Nicotine gum companies are spending money on research and development (R&D) activities to enhance the effectiveness of product as well as user experience. Users are adopting these gums owing to innovations like enhanced flavors and unique delivery systems. In addition, enhanced understanding of nicotine addiction and withdrawal processes are benefiting in the creation of gum formulations that are more efficient. The escalating demand for more efficient smoking cessation solutions is bolstering the nicotine gum market growth. Besides this, companies in the market are getting product approvals from the recognized authorities. For instance, Perrigo Company plc (PRGO) received final approval from the Food Drug Administration (FDA) for nicotine coated mint lozenges 2 mg and 4 mg OTC on 16 May 2023. The product helps in reducing withdrawal symptoms in consumers who are trying to quit smoking. Moreover, it will be marketed under retailer's store brand labels as a comparable offering to Nicorette coated ice mint lozenge.
IMARC Group provides an analysis of the key nicotine gum market trends in each market segment, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on type, application, and distribution channel.
The report has provided a detailed breakup and analysis of the market based on the type. This includes 2 mg nicotine gum, 4 mg nicotine gum, and 6 mg nicotine gum. According to the report, 2 mg nicotine gum represented the largest segment.
Those looking to cut back on their nicotine intake during their journey to quit smoking can find 2 mg category a suitable choice. 2mg nicotine gum is an ideal alternative for controlling withdrawal symptoms while progressively weaning off nicotine dependence, making it the perfect choice among light to moderate smokers. Furthermore, it is advised for people who need a step-down strategy and in the early phases of quitting in order to enable a more regulated shift to a life free of nicotine.
Withdrawal Clinics
Medical Practice
Individual Smokers
Others
Medical practice holds the largest share of the industry
A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes withdrawal clinics, medical practice, individual smokers, and others. According to the report, medical practice accounted for the largest market share.
Nicotine gums are used in more comprehensive smoking cessation programs in medical settings. Physicians may recommend this gum to patients as part of individualized smoking cessation regimens or during routine consultations. The progressive and regulated release of nicotine from the gum is consistent with evidence-based therapies. In the medical practice application, the importance of healthcare professionals in helping people quit is emphasized, along with the health advantages and individualized assistance that come with using nicotine gum.
Retail Pharmacies
Specialty Stores
Online Stores
Others
Retail pharmacies represent the leading market segment
The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes retail pharmacies, specialty stores, online stores, and others. According to the report, retail pharmacies represented the largest segment.
Nicotine gums are readily available at retail pharmacies. Consumers in search of smoking cessation products can easily locate them in close proximity to their homes. This gum is easily available and pharmacists can offer their advice related to medication, which makes it a favored option for those seeking person-to-person support and quick access to quit smoking products.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America leads the market, accounting for the largest nicotine gum market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for nicotine gum.
North America stands as a significant market due to robust smoking cessation efforts, heightened health awareness, and a substantial consumer base. The region has a well-established healthcare infrastructure and proactive regulatory measures that contribute to the popularity of these gums as a preferred smoking cessation aid. In addition, there is an increase in the number of individuals seeking effective solutions to quit smoking in the North America region. Besides this, the wide availability of these gum across various distribution channels including retail pharmacies and online stores, assists in increasing nicotine gum market revenue. On 18 March 2024, Cambrex, a leading global contract development and manufacturing organization (CDMO), announced the completion of a 5-year, US$ 100-Million-dollar investment strategy, one year ahead of schedule. The project adds more than 150,000 square-feet of capacity and capability expansions across 70% of its North American and European drug development and manufacturing network, which will be completed by the end of 2024. The investments span all scales of clinical and commercial drug substance manufacturing and include advanced technologies to solve for challenges related to complex molecules.
The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the nicotine gum industry include British American Tobacco, Cambrex Corporation, GlaxoSmithKline, ITC Limited, Johnson & Johnson Services, Novartis, Perrigo, Pfizer, Takeda Pharmaceutical Company.
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
Key players in the market are engaging in strategic initiatives that are focused on product innovation, marketing, and collaborative efforts. Continuous R&D investments by key manufacturers aim to enhance the effectiveness and appeal of the product formulations. These companies leverage technological advancements to create novel delivery mechanisms, improved flavors, and better taste masking, meeting consumer preferences and driving market growth. Moreover, robust marketing campaigns and partnerships with healthcare organizations contribute to the rising awareness about smoking cessation benefits among individuals while expanding the consumer base. Collaborative efforts between industry stakeholders and regulatory bodies ensure compliance with health standards and foster a positive market environment. On 3 July 2023, Haleon, the world's biggest standalone consumer health business, explored the sale of its nicotine gum business as it aims to streamline its business. The company is working with an adviser to find potential suitors for its Nicotinell brand of nicotine gum, which could be worth about US$ 800 Million in sales.